Rui Mei

As Chief Scientific Officer at CellMax Life, Dr Mei leads a global team of R&D scientists, CLIA and CAP laboratory professionals, bioinformaticians and software engineers. She is responsible for the development of CellMax Life’s multi-biomarker platforms, including the precancer and cancer cell detection, next-generation sequencing (NGS), methylation, and protein expression platforms. Prior to joining CellMax Life, Dr. Mei was Vice President of R&D and genomic service operations, and part of the founding team at Centrillion Biosciences, where she established that company's next-generation sequencing services for pharmaceutical companies, researchers, and physicians. At Affymetrix, a pioneer in multi-biomarker analysis tools, Dr. Mei led the development of multiple products for genotyping, re-sequencing, and gene expression analysis. She received her Ph.D. in Biochemistry from the University of Michigan, Ann Arbor, and post-doctoral training in Nucleic Acid Enzymology at Stanford University. Dr. Mei has published over 40 articles in peer-reviewed scientific journals and holds 20 patents.